全球新型抗肿瘤药物研发进展及趋势  

Noval anti-tumor drugs:global advances and trends

作　　者：李积宗 张博文[2] 方淑蓓 韩佳[2] 毛开云[2] 江洪波[2] 陈大明[2] LI Jizong;ZHANG Bowen;FANG Shubei;HAN Jia;MAO Kaiyun;JIANG Hongbo;CHEN Darning(Shanghai Center of Biomedicine Development,Shanghai 201203,China;Shanghai Information Center for Life Sciences,Shanghai Institute of Nutrition and Health,Chinese Academy of Sciences,Shanghai 200031,China)

机构地区：[1]上海市生物医药科技发展中心,上海201203 [2]中国科学院上海生命科学信息中心、中国科学院上海营养与健康研究所,上海200031

出　　处：《上海医药》2022年第S02期1-8,共8页Shanghai Medical & Pharmaceutical Journal

摘　　要：新型抗肿瘤药物已成功用于规避常规策略的某些局限性,同时提供更高的敏感性和特异性、更高的生物利用度和改善的综合治疗效果。本文总结了过去70年的抗肿瘤药物开发里程碑,综述了基于肿瘤标志性特征的14类抗肿瘤药物开发路径,并且从多学科交叉融合的视角探索了抗肿瘤药物开发中的前景。Noval anti-tumor drugs have been successfully employed to circumvent certain limitations of conventional strategies while providing higher sensitivity and specificity,greater bioavailability,and improved comprehensive effects for therapeutic outcomes.This paper summarized anti-tumor drug development milestones in the past seven decades,reviewed antitumor drug based therapies accroding to 14 different targeting approaches,and discussed the imperative role of multidisciplinary researches that could drive anti-tumor drug developments.

关 键 词：抗肿瘤 药物 多学科研究 

分 类 号：R979.1[医药卫生—药品]